AAT-008

AAT-008 is a potent, selective, and orally active prostaglandin EP4 receptor antagonist with Kis of 0.97 and 6.1 nM for recombinant human EP4 and recombinant rat EP4, respectively. AAT-008 exerts tumor growth delay in mice bearing CT26WT colon tumors when combined with radiotherapy. AAT-008 can be used for the study of acute and chronic inflammatory pain and cancer [1][2].

Product Specifications

CAS Number

[847727-81-5]

UNSPSC

12352005

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/aat-008.html

Concentration

10mM

Purity

98.55

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=C([C@@H](NC(C2=CC(Cl)=CN=C2OC3=CC=CC(F)=C3)=O)C)C=C1

Molecular Formula

C21H16ClFN2O4

Molecular Weight

414.81

References & Citations

[1]Okumura Y, et al. Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. Bioorg Med Chem Lett. 2017;27 (5) :1186-1192. |[2]Manabe Y, et al. Biological effects of prostaglandin E2-EP4 antagonist (AAT-008) in murine colon cancer in vivo: enhancement of immune response to radiotherapy and potential as a radiosensitizer. Transl Cancer Res. 2023 Feb 28;12 (2) :351-358.